Background: Previous studies suggest that efficacy is more important than side-effect risks to psoriasis patients. However, those studies did not consider potentially fatal risks of biologic treatments. Objective: To quantify the risks patients are willing to accept for improvements in psoriasis symptoms. Methods: Adults with a self-reported physician diagnosis of psoriasis were recruited through the National Psoriasis Foundation. Using a discrete-choice experiment, patients completed a series of nine choice questions, each including a pair of hypothetical treatments. Treatments were defined by severity of plaques, body surface area (BSA), and 10-year risks of tuberculosis, serious infection and lymphoma. Results: For complete clearance of 25% BSA with mild plaques, respondents (n = 1608) were willing to accept a 20% (95% confidence interval: 9-26%) risk of serious infection, 10% (5-15%) risk of tuberculosis and 2% (1-3%) risk of lymphoma. For complete clearance of 25% BSA with severe plaques, respondents were willing to accept a 54% (48-62%) risk of serious infection, 36% (28-49%) risk of tuberculosis and 8% (7-9%) risk of lymphoma. Limitations: Respondents were asked to evaluate hypothetical scenarios. Actual treatment choices may differ. Conclusion: Respondents were willing to accept risks above likely clinical exposures for improvements in psoriasis symptoms. Individual risk tolerances may vary.
Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy
Kauf, TL., Yang, JC., Kimball, AB., Sundaram, M., Bao, YJ., Okun, M., ... Johnson, FR. (2015). Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy. Journal of Dermatological Treatment, 26(6), 507-513. https://doi.org/10.3109/09546634.2015.1034071